-
Cutting Edge: Anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+ T regulatory cells.
J Immunol. 2006 Mar 15;176(6):3301-5
PMID: 16517695
-
CD8+ T cell contraction is controlled by early inflammation.
Nat Immunol. 2004 Aug;5(8):809-17
PMID: 15247915
-
Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation.
J Exp Med. 2005 Oct 3;202(7):919-29
PMID: 16186184
-
CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death.
Nature. 2005 Mar 3;434(7029):88-93
PMID: 15744305
-
Gammaherpesvirus persistence alters key CD8 T-cell memory characteristics and enhances antiviral protection.
J Virol. 2006 Sep;80(17):8303-15
PMID: 16912282
-
Requirement for CD4 T cell help in generating functional CD8 T cell memory.
Science. 2003 Apr 11;300(5617):337-9
PMID: 12690201
-
Regulatory CD4+CD25+ T cells restrict memory CD8+ T cell responses.
J Exp Med. 2002 Dec 16;196(12):1585-92
PMID: 12486101
-
CD8+ T-cell memory in tumor immunology and immunotherapy.
Immunol Rev. 2006 Jun;211:214-24
PMID: 16824130
-
Immunological consequences of tumor excision: from active immunity to immunological memory.
Int J Cancer. 1986 Feb 15;37(2):275-81
PMID: 3943923
-
Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control.
J Exp Med. 2003 Oct 6;198(7):1023-34
PMID: 14530375
-
Differential contributions of central and effector memory T cells to recall responses.
J Exp Med. 2005 Jul 4;202(1):123-33
PMID: 15983064
-
Migratory properties of naive, effector, and memory CD8(+) T cells.
J Exp Med. 2001 Oct 1;194(7):953-66
PMID: 11581317
-
Circulating Tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activity.
Cancer Res. 2002 Mar 15;62(6):1743-50
PMID: 11912149
-
Resection of solid tumors reverses T cell defects and restores protective immunity.
J Immunol. 2000 Feb 15;164(4):2214-20
PMID: 10657677
-
Understanding the generation and function of memory T cell subsets.
Curr Opin Immunol. 2005 Jun;17(3):326-32
PMID: 15886125
-
Molecular and functional profiling of memory CD8 T cell differentiation.
Cell. 2002 Dec 13;111(6):837-51
PMID: 12526810
-
A DNA vaccine targeting Fos-related antigen 1 enhanced by IL-18 induces long-lived T-cell memory against tumor recurrence.
Cancer Res. 2005 Apr 15;65(8):3419-27
PMID: 15833877
-
CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.
J Immunol. 2005 Mar 1;174(5):2591-601
PMID: 15728465
-
gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand.
J Exp Med. 1998 Jul 20;188(2):277-86
PMID: 9670040
-
Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity.
J Immunol. 1999 Nov 15;163(10):5211-8
PMID: 10553041
-
Cutting edge: regulation of CD8+ T cell effector population size.
J Immunol. 2004 Sep 1;173(5):2923-7
PMID: 15322149
-
Antigen-independent memory CD8 T cells do not develop during chronic viral infection.
Proc Natl Acad Sci U S A. 2004 Nov 9;101(45):16004-9
PMID: 15505208
-
Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response.
J Exp Med. 2005 May 16;201(10):1591-602
PMID: 15883172
-
Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes.
J Exp Med. 1998 Nov 2;188(9):1641-50
PMID: 9802976
-
Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma.
J Immunol. 2003 Dec 1;171(11):5940-7
PMID: 14634105
-
Regulatory T cells, tumour immunity and immunotherapy.
Nat Rev Immunol. 2006 Apr;6(4):295-307
PMID: 16557261
-
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.
Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8372-7
PMID: 12826605
-
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.
J Exp Med. 2003 Aug 18;198(4):569-80
PMID: 12925674
-
CD4+CD25+ T cells regulate virus-specific primary and memory CD8+ T cell responses.
J Exp Med. 2003 Sep 15;198(6):889-901
PMID: 12975455
-
Multiple pathways to tumor immunity and concomitant autoimmunity.
Immunol Rev. 2002 Oct;188:122-35
PMID: 12445286
-
Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells.
J Clin Invest. 2005 Dec;115(12):3623-33
PMID: 16308572
-
Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease.
Cancer Res. 2004 Mar 15;64(6):2205-11
PMID: 15026364
-
Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells.
J Exp Med. 2004 Sep 20;200(6):771-82
PMID: 15381730
-
Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells.
Cancer Res. 2001 Feb 1;61(3):1095-9
PMID: 11221838
-
Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma.
J Immunother. 2005 Nov-Dec;28(6):582-92
PMID: 16224276
-
Effect of chronic viral infection on epitope selection, cytokine production, and surface phenotype of CD8 T cells and the role of IFN-gamma receptor in immune regulation.
J Immunol. 2004 Feb 1;172(3):1491-500
PMID: 14734726
-
Naive and memory CD4+ T cell survival controlled by clonal abundance.
Science. 2006 Apr 7;312(5770):114-6
PMID: 16513943
-
Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.
J Exp Med. 1999 Aug 2;190(3):355-66
PMID: 10430624
-
Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells.
Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9571-6
PMID: 15980149
-
Immunity to methylcholanthrene-induced sarcomas.
J Natl Cancer Inst. 1957 Jun;18(6):769-78
PMID: 13502695
-
Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses.
J Exp Med. 2001 Sep 17;194(6):823-32
PMID: 11560997
-
Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma.
J Exp Med. 1997 Feb 3;185(3):453-9
PMID: 9053445
-
Two subsets of memory T lymphocytes with distinct homing potentials and effector functions.
Nature. 1999 Oct 14;401(6754):708-12
PMID: 10537110
-
CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection.
Nat Immunol. 2004 Sep;5(9):927-33
PMID: 15300249
-
Effect of anti-CD4 on CD4 subsets. I. Anti-CD4 preferentially deletes resting, naive CD4 cells and spares activated CD4 cells.
J Immunol. 1994 Jan 15;152(2):405-12
PMID: 7904288
-
Generation and decay of the immune response to a progressive fibrosarcoma. II. Failure to demonstrate postexcision immunity after the onset of T cell-mediated suppression of immunity.
J Exp Med. 1984 May 1;159(5):1312-21
PMID: 6232336
-
Vitiligo in patients with metastatic melanoma: a good prognostic sign.
J Am Acad Dermatol. 1983 Nov;9(5):689-96
PMID: 6643767
-
Combined IL-21 and low-dose IL-2 therapy induces anti-tumor immunity and long-term curative effects in a murine melanoma tumor model.
J Transl Med. 2006 Jun 13;4:24
PMID: 16772043
-
Lineage relationship and protective immunity of memory CD8 T cell subsets.
Nat Immunol. 2003 Mar;4(3):225-34
PMID: 12563257
-
Prognostic significance of hypopigmentation in malignant melanoma.
Arch Dermatol. 1987 Aug;123(8):1053-5
PMID: 3631983